The 24.2% weight reduction at 48 weeks, combined with improvements in triglycerides, liver enzymes, and insulin sensitivity markers, positions Retatrutide as the more mechanistically complete compound in the Retatrutide vs Tirzepatide framework, pending Phase 3 confirmation
You can only get Semaglutide GLP-1 through a healthcare provider because it is a prescription drug
Unlimited 24/7 support No hidden fees No insurance required Same price, every dose Important safety information Important Safety Information Refer to the following important safety details for information on intended use, potential side effects and risks, considerations for specific groups, and possible drug interactions linked to the prescription treatments mentioned
4 weeks Minimum interval between dose increases 2mg to 12mg Phase 2 dose range (Jastreboff 2023) ~12 weeks Time to reach 12mg on standard protocol 24.2% Weight loss at 12mg, 48 weeks (Phase 2) Investigational Drug Warning Retatrutide (LY3437943) is not FDA-approved as of April 2026
What it does mean: the brand states that treatment plans are reviewed by licensed providers and that coaching support is included
10.1111/bph.15647 11 BossartM.WagnerM.ElvertR.EversA.HbschleT.KloeckenerT.et al (2022)
